Skip to main content

Table 1 Demographics, characteristics, and interventions of eyes with visual impairment from center-involved diabetic macular edema stratified by visual acuity response at one year following treatments

From: Factors associated with 1-year visual response following intravitreal bevacizumab treatment for diabetic macular edema: a retrospective single center study

Characteristics Overall (N = 226 Eyes) Gain ≥ 10 Letters at 1 Year (N = 110 Eyes) Gain < 10 Letters at 1 Year (N = 116 Eyes) P Value*
Demographics
 Age ≥ 60 years, n (%) 78 (34.5) 30 (27.3) 48 (41.4) 0.041
 Male, n (%) 122 (54) 66 (60) 56 (48.3) 0.112
 Severe NPDR to PDR stage, n (%) 158 (69.9) 75 (68.2) 83 (71.6) 0.638
 Previous macular laser photocoagulation, n (%) 42 (18.6) 13 (11.8) 29 (25) 0.019
 Previous PRP, n (%) 63 (27.9) 28 (25.5) 35 (30.2) 0.528
 Phakia, n (%) 202 (89.4) 102 (92.7) 100 (86.2) 0.115
Ocular characteristics at baseline
 Mean (SD) VA, letter 51.8 (19.1) 46 (21) 57.3 (15.2)  < 0.001
 VA ≥ 69 letters, n (%) 63 (27.9) 23 (20.9) 40 (34.5) 0.025
 Mean CSFT (SD), µm 496.2 (145.2) 513.9 (164.5) 479.4 (122.6) 0.159
 CSFT ≥ 400 µm 163 (72.1) 80 (72.3) 83 (81.6) 0.983
 ERM, n (%) 28 (12.4) 7 (6.4) 21 (18.1) 0.012
 DRIL, n (%) 65 (28.8) 24 (21.8) 41 (35.3) 0.026
 HF, n (%) 99 (43.8) 52 (47.3) 47 (40.5) 0.257
 IRC ≥ 600 µm, n (%) 23 (10.2) 9 (8.2) 14 (12.1) 0.399
 Disruption of ELM, n (%) 61 (26.9) 30 (27.3) 31 (26.7) 0.858
 Disruption of EZ, n (%) 56 (24.8) 18 (16.4) 38 (32.8) 0.003
 SRF, n (%) 113 (50) 59 (53.6) 54 (46.6) 0.316
 Foveal exudate, n (%) 15 (6.6) 6 (5.5) 9 (7.8) 0.507
Ocular characteristics at week 12
 Mean (SD) VA, letter 61.7 (17.8) 63.6 (17.8) 59.9 (17.7) 0.172
 VA gain < 5 letters, n (%) 80 (35.4) 13 (11.8) 67 (57.8)  < 0.001
 CSFT reduction < 10%, n (%) 78 (34.5) 27 (24.6) 51 (44.0) 0.004
 DRIL, n (%) 42 (18.6) 13 (11.8) 29 (25) 0.012
 HF, n (%) 63 (27.9) 31 (28.2) 32 (27.6) 0.812
 IRC ≥ 600 µm, n (%) 15 (6.6) 4 (3.6) 11 (9.5) 0.046
 Disruption of ELM, n (%) 43 (19) 12 (10.9) 31 (26.7) 0.002
 Disruption of EZ, n (%) 44 (19.5) 12 (10.9) 32 (27.6) 0.002
 SRF, n (%) 41 (18.1) 24 (21.8) 17 (14.7) 0.256
 Foveal exudate, n (%) 17 (7.5) 6 (5.5) 11 (9.5) 0.428
During 12 months
 Mean (SD) number of injections 7.3 (3.2) 6.9 (3.2) 7.5 (3.2) 0.183
 Receiving additional macular laser photocoagulation, n (%) 127 (56.2) 59 (53.6) 68 (58.6) 0.494
  1. VA visual acuity,SD standard deviation, NPDR  non-proliferative diabetic retinopathy,PDR proliferative diabetic retinopathy, PRPpanretinal photocoagulation, CSFTcentral subfield thickness, ERMepiretinal membrane, DRILdisorganization of retinal inner layer, HFhyperreflective foci, IRCintraretinal cyst, ELMexternal limiting membrane, EZellipsoid zone, SRFsubretinal fluid
  2. *generalized estimating equation (GEE)